What it sells
We make unmakeable proteins with radical advanced biomanufacturing.
Business model breakdown
Buyer: who owns the budget?
UnverifiedR&D and manufacturing/BD leads at diagnostics (IVD), biopharma and crop protection companies.
Trigger: what makes them buy now?
Proteins that traditional systems cannot express, or need at gram scale for regulatory dossiers and IVD commercial production.
Workflow: what inputs become what output?
Milestones: strain generation, expression optimization, process development, then production and characterization at gram scale (one case study reports sequence to scale in seven months).
Economics: what it saves and how it charges
Custom contract manufacturing/development per project; 6,000 sq ft Instar 1.0 biofactory, claims 30x output of conventional protein technology.
Distribution: how it reaches customers
Consultative sales: "Request a Protein Consult"; case studies and newsroom.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2020 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.